Svas Biosana SpAMIL:SVS -1.78%79 Return-on-Tangible-Equity is 13.74% as of Dec. 2025, which is 19% above its 10-year median of 11.59. GuruFocus rates MIL:SVS with a GF Score™ of 79/100 and a GF Value™ of €9.64 (Fairly Valued). The stock has 4 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Svas Biosana SpA ranks better than 74.9% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Svas Biosana SpA's annualized net income for the quarter that ended in Dec. 2025 was €6.6 Mil. Svas Biosana SpA's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €47.8 Mil. Therefore, Svas Biosana SpA's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 13.74%.
The historical rank and industry rank for Svas Biosana SpA's Return-on-Tangible-Equity or its related term are showing as below:
MIL:SVS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.53 Med: 11.59 Max: 14.38
Current: 13.87
During the past 8 years, Svas Biosana SpA's highest Return-on-Tangible-Equity was 14.38%. The lowest was 8.53%. And the median was 11.59%.
MIL:SVS's Return-on-Tangible-Equity is ranked better than 74.9% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs MIL:SVS: 13.87
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Svas Biosana SpA Return-on-Tangible-Equity Related Terms
Svas Biosana SpA Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Svas Biosana SpA's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:SVS vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Svas Biosana SpA's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Svas Biosana SpA Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Svas Biosana SpA's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Svas Biosana SpA's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.74% mean?
Svas Biosana SpA (MIL:SVS) has a Return-on-Tangible-Equity of 13.74% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Svas Biosana SpA and its competitors. This is 19% above median its historical median of 11.59. Over the past decade, Svas Biosana SpA's Return-on-Tangible-Equity has ranged from 8.53 to 14.38. According to the industry distribution chart, Svas Biosana SpA ranks #190 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 25.1%.
Is Svas Biosana SpA's Return-on-Tangible-Equity too high?
Svas Biosana SpA's current Return-on-Tangible-Equity of 13.74% is 19% above median its 10-year median of 11.59. Over the past 10 years, this metric has ranged from a low of 8.53 to a high of 14.38. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.09. Svas Biosana SpA's value of 13.74% is 235.9% above this industry median. Based on the distribution chart, Svas Biosana SpA ranks #190 out of 757 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Svas Biosana SpA has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Svas Biosana SpA's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Svas Biosana SpA ranks #190 out of 757 companies for Return-on-Tangible-Equity. This puts Svas Biosana SpA in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.09. Svas Biosana SpA's value of 13.74% is 235.9% above this benchmark. Historically, Svas Biosana SpA's own Return-on-Tangible-Equity has ranged from 8.53 to 14.38 over the past decade. While the company's 10-year median is 11.59 vs. the industry median of 4.09, Svas Biosana SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Svas Biosana SpA's current Return-on-Tangible-Equity of 13.74% is 235.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Svas Biosana SpA and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Svas Biosana SpA's current Return-on-Tangible-Equity is 13.74%, which is 19% above median its own 10-year median of 11.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Svas Biosana SpA stock overvalued right now?
Based on GuruFocus' analysis, Svas Biosana SpA (MIL:SVS) is currently considered Fairly Valued. The stock's GF Value™ is €9.64, compared to a current price of €8.82 — trading 8.5% below its estimated fair value. The current Return-on-Tangible-Equity is 13.74%, which is 19% above median its 10-year median of 11.59 and 235.9% above the Medical Devices & Instruments industry median of 4.09. Svas Biosana SpA's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Svas Biosana SpA (MIL:SVS), the current Return-on-Tangible-Equity is 13.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Svas Biosana SpA (MIL:SVS) Overvalued in 2026?
Based on GuruFocus' analysis, Svas Biosana SpA stock appears to be undervalued.
The current stock price of €8.82 is trading 8.5% below its estimated GF Value™ of €9.64.
GuruFocus considers Svas Biosana SpA to be Fairly Valued.
Key valuation signals for MIL:SVS:
Return-on-Tangible-Equity: 13.74% (19% above median its 10-year median of 11.59)
GF Value™: €9.64 vs. price of €8.82 (8.5% below fair value)
Industry Position: 235.9% above the Medical Devices & Instruments median (#190 of 757)
No single metric tells the full story. See the MIL:SVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:SVS has been successfully added to your 
